Unresectable or metastatic HER2+BC after 2 or more anti-HER2 regimens/LA or metastatic HER2+gastric or gastroesophageal junction adenocarcinoma after a trastuzumab-based regimen. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.